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Introduction  
 
Stem and progenitor cell (SPC) biology became a common point of interest for cardiovascu-
lar (CV) physicians and basic scientists with the ultimate goal of translation into clinical appli-
cation by use of the innate reparatory mechanisms of the heart and vascular endothelium. 
Bone-marrow-derived stem cell therapy of the heart became a reality 9 years ago; however, 
we still do not know the exact mechanisms of physiological response of the bone marrow 
(BM) compartment evoked by myocardial ischemia. Acute myocardial infarction (MI) pro-
duces a generalized inflammatory reaction, a part of which is mobilization of SPCs, in-
creased local production of chemoattractants in the ischemic myocardium, as well as neural 
and humoral signals activating the stem cell egress from the BM. Numerous studies con-
firmed that MI induces rapid mobilization of hematopoietic stem cells (HSCs), endothelial 
progenitor cells (EPCs), mesenchymal stromal cells (MSCs), circulating angiogenic cells and 
pluripotent very small embryonic-like cells (VSELs); however, the contribution of circulating 
cells to the myocardial and endothelial repair is still incompletely understood, although ex-
perimental studies have suggested an important role of BM-derived stem cells in the cardiac 
repair response after MI. Acute MI is associated with substantial tissue necrosis, so the sig-
nals for SPCs may be regarded as a part of the inflammatory reaction; however, even in 
healthy subjects and patients with stable coronary artery disease (CAD) there is a constant 
mobilization of a small number of SPCs, which probably participate in endothelial and cardiac 
renewal. This review discusses the mobilization of SPCs in acute ischemia (MI, stroke), as 
well as in stable cardiovascular disease, and highlights the possibility of using the SPC as a 
marker of cardiovascular risk.1,2   
 
Mobilization of SPCs in acute coronary syndromes  
 
Heterogeneity of circulating SPCs  
Ischemia and myocardial necrosis form a milieu within the BM and cardiac tissue accompa-
nied by increased levels of chemoattractants (bioactive phospholipids, kinins, chemokines, 
cytokines, growth factors, complement cascade), which promote the release of a heteroge-
nous population of BM cells. This phenomenon was observed many years ago when in-
creased leukocyte count in acute MI was described and was considered to be an unspecific 
inflammatory reaction. In general, the majority of mobilized cells are committed lineages, 
including granulocytes, lymphocytes, CD14+ monocytes and a very small number of cells 
with immature phenotype.1 Many studies that investigated mobilization of BM cells in acute 
coronary syndromes had a pivotal limitation, which is the use of a single surface marker for 
identification of the cell types, for example, CD34+, which makes it impossible to directly 
compare the findings and to form a viable hypothesis on the role of a particular cell popula-
tion in the reparatory process.3,4 The methodology of SPC measurement is beyond the scope 
of this review; however, some important issues that determine the validity of the results have 
to be considered. In particular, so far there is no consensus on the identification criteria even 
of the most frequently investigated population of EPCs. Use of less stringent criteria, for ex-
ample, by employing assays based on a single marker, can overestimate the number of 
SPCs, which are extremely rare both in the BM and in peripheral blood (PB).4 There is an 
overlap in expression of surface markers and a set of several markers needs to be employed 
to identify a particular population of cells.5–7   
 
Endothelial progenitor cells  
Ten years ago, Shintani et al.3 described for the first time the rapid mobilization of CD34+ 
cells in acute MI. Cells were further characterized in cultures as EPCs. The number of re-
leased cells reached a maximum 7 days after the onset of MI parallel to significant increase 
of plasma levels of vascular endothelial growth factor (VEGF). Follow-up 1 month later 
showed that the number of EPCs was still elevated in comparison with baseline. These ob-
servations were subsequently confirmed by Massa et al.,8 who showed spontaneous mobili-
zation of EPCs, which reached a maximum very early, B3 h after the onset of myocardial 
ischemia, and decreased to values comparable to healthy subjects within 60 days. After im-
munomagnetic purification of circulating CD34+ cells it was shown that the level of co-
expression of CD133 and VEGFR2 is significantly higher in patients with acute MI, suggest-
ing that increase of EPCs is responsible for the higher number of CD34+ cells. Also, the in 
vitro study showed an increased number of endothelial colonies and a gradual increase of 
VEGF levels. Several other studies confirmed the very rapid release of EPCs in acute MI, in 
contrast to the landmark study of Shintani that suggested delayed mobilization of CD34+ 
cells. Interestingly, mobilized CD34+ cells expressed higher levels of CXCR4, LFA-1, VLA-4 
and ICAM-1 receptors in comparison with patients with stable CAD, which theoretically would 
promote the homing of these cells to the ischemic area.9 The type of primary treatment of 
AMI does not seem to affect the mobilization, because a similar pattern of CD34+ cell in-
crease was found in patients who received thrombolytic therapy instead of primary angio-
plasty.10 Also, an increased number of EPCs was observed for as long as 3 months after the 
episode of unstable angina, which, in contrast to MI, involves myocardial ischemia but not 
extensive necrosis, so it is likely that the chemoattractants are more effectively released by 
viable myocardial tissue than in an acute setting.11 Since the first description of CD34+ EPCs 
by Asahara et al.12 in 1997, a variety of studies measured the EPCs in patients with CAD 
using different protocols.7 So far the data from these studies show that EPSc form a hetero-
genous population of cells. The most widely accepted phenotype for identification of EPCs by 
FACS comprises CD34+/KDR+ (kinase insert domain containing receptor) and CD133+/KDR+ 
cells.5,13 Also accumulating evidence supports the hypothesis that a population of circulating 
CD14+ monocytes can be a source of EPCs.14,15 Moreover, Krankel et al.16 showed that type 
B2 receptor for bradykinin is expressed on EPCs. The presence of type B2 receptor is con-
sistent with the chemoattractant effects of bradykinin, which in turn is guided by the migration 
of proangiogenic progenitor cells. Therefore, inclusion of type B2 receptor into the array of 
surface markers detected on EPCs might help identify the population of ‘angiogenic’ EPCs. 
Currently, modified protocols (for example, the modified International Society of Hematother-
apy and Graft Engineering protocol) are developed to more effectively identify the EPCs. The 
use of this protocol showed that the target population of EPCs is a subpopulation of 
CD45dim/CD34+/KDR+ cells.17 Only when uniform cell enumeration protocols are used might 
the results from different laboratories be compared. A major difference between the studies 
is the use of the FACS-based or culture-based approach of EPC identification. Even the pro-
tocols based on cell cultures are non-uniform and results difficult to compare. It seems that 
interpretation of findings from studies investigating circulating EPCs should be adjusted ac-
cording to the particular protocol. For example, decrease of EPCs in patients with CAD is 
consistently reported in studies using either the FACS-based or the culture-based protocols; 
however, in patients with ACS the increase in EPC number reported in studies using the 
‘standard’ FACS approach (CD34+/KDR+) was not observed when the modified International 
Society of Hematotherapy and Graft Engineering protocol (CD45dim/ CD34+/KDR+) was em-
ployed.17 In several studies the protocols based on cell culture were used with or without 
concomitant identification of EPCs by FACS. So far the most widely used approach for enu-
meration of EPCs is a FACS-based protocol, which gives an idea about the cell number and 
allows for correlation with clinical markers and outcomes, but does not necessarily overlap 
with ‘true’ angiogenic cells identified by cell culture.7,18 In addition, the population of circulat-
ing progenitor cells can be identified by staining for aldehyde dehydrogenase, which identi-
fies cells expressing CD34 and CD133 markers and correlates with the number of 
CD133+CD34+ EPCs.19  
Last but not the least, circulating EPCs on different stages of maturation should be distin-
guished from circulating endothelial cells (CECs), which are sloughed from the arterial wall. 
CECs present mature phenotype (CD34⎯, CD133⎯, CD146+, von Willebrand+) and have no 
potential to form colonies in vitro. CEC number is increased in ACS, stroke and critical limb 
ischemia in a similar manner as immature SPCs. Probably the endothelial cellular turnover, 
which can be roughly estimated as the ratio of CEC to EPC, will yield more information on 
individual reparatory potential than measurement of either single population of cells. The 
differentiation between EPCs and CEC based just on the flow cytometry might be subopti-
mal, because of some degree of overlap of the populations expressing ‘EPC-specific’ and 
‘CEC-specific’ markers.20 The differentiation between populations of circulating SPCs is more 
effective when identification with FACS is supported by colony-forming unit assays and stud-
ies of angiogenic potential. These methods are, however, not compatible with routine clinical 
practice, such as risk stratification. Indeed, the study of Fadini et al.21 in 21 patients with 
metabolic syndrome showed that the number of CD34+ cells is a better predictor of cardio-
vascular risk than analysis of cell subpopulations (CD133+, CD34+/CD133+, CD34+/KDR+, 
CD133+/KDR+, and CD34+/CD133+/ KDR+). Therefore, in order to use the number of EPCs 
as a surrogate marker of CV risk, it would be more appropriate to use the simpler approach 
and choose a surface marker (CD34+), which might not differentiate between particular sub-
sets of cells, but show best correlation with CV risk burden.  
 
Hematopoietic stem cells  
Initial studies showing the release of CD34+ in acute coronary syndromes were followed by 
more detailed cell characterization with FACS protocols consistent with the International So-
ciety of Hematotherapy and Graft Engineering protocol guidelines. Massa et al.8 showed that 
HSCs are mobilized soon after the onset of acute MI and the release kinetics is similar to 
EPCs. The populations of cells isolated from PB were CD34+/CD117+, CD34+/CXCR4+, 
CD34+/CD38+ and CD34+/CD45+. Mobilization of HSC has been confirmed by cell cultures, 
which revealed increased number of erythroid burst-forming units and granulocyte macro-
phage colony-forming units soon after onset of acute MI. We have also demonstrated rapid 
mobilization of HSC-enriched populations of CD34+/CXCR4+ and CD34+/CD117+ stem cells 
in the setting of acute MI, with maximum cell efflux within the first 12 h after the chest pain 
and decrease over 1 week.22 Therefore, consistent data confirm that not only EPCs but also 
HSCs contribute to the pool of SPCs mobilized by acute MI. Conversely, Leone et al.23 
showed that in a substantial number of patients the maximum mobilization of HSCs occurred 
later, on the fifth day after acute MI. Interestingly, the elevated number of HSCs was not re-
lated to increased leukocyte count.8  
 
Stem cells expressing early developmental and tissue specific markers (VSELs)  
Our initial studies showed that in patients with acute MI parallel to the mobilization of 
CD34+/CXCR4+ and CD34+/CD117+ cells there is a marked upregulation of genes coding for 
specific cardiac (GATA4, MEF2C and Nkx2.5/Csx), muscle (Myf5, Myogenin and MyoD) and 
endothelial (VE-cadherin and von Willebrand factor) markers in peripheral blood mononu-
clear cells.22 Following this finding, a small population of CXCR4+ cells displaying the pheno-
type of primitive pluripotent cells was characterized and named VSELs. We established the 
protocol of FACS-based live cell sorting, which is most efficient for isolation of this rare popu-
lation of cells. The detailed protocol and characteristics of VSELs were described else-
where.24,25 In brief, VSELs are non-hematopoietic lin⎯/CD45⎯/CD133+ cells enriched for early 
embryonic markers (Oct-4, Nanog, SSEA-4, Rex1, Dppa3 and Rif-1) and expressing CXCR4 
receptor. The morphology and size of VSELs resemble those of pluripotent embryonic stem 
cells and are markedly different from and significantly smaller than HSCs (open-type chroma-
tin, large nucleus, narrow rim of cytoplasm with multiple mitochondria; 3–6 mm vs 6–
8mm).25,26 In healthy adult humans PB contains a very low number of VSELs, B1–1.5 
cells/ml. In the setting of acute MI, VSELs undergo rapid mobilization within 12 h similarly to 
HSCs and EPCs, with the exception that the absolute number of cells is lower than that for 
the other two populations. Release of VSELs into PB coexists with marked increase of the 
expression levels of mRNA of PSC markers (Oct-4, Nanog), as well as early cardiac (GATA-
4, Nkx2.5/Csx and MEF2C) and endothelial markers (VE-cadherin).27 The primitive pheno-
type of these cells and ability of murine VSELs to undergo expansion and differentiation into 
cells from three germ layers including cardiomyocytes raises the exciting possibility that they 
constitute a population with high reparatory potential. VSELs express chemokine receptor 
CXCR4, so they can react to the homing signals produced by ischemic myocardial tissue.28  
 
Mesenchymal stem cells  
Mesenchymal stem cells might potentially be optimal cells for cardiac repair, given their im-
munoprivileged status. It seems most probable that MSCs are mobilized into peripheral blood 
along with other populations of BM cells. However, the data regarding the kinetics of MSCs 
mobilization are not consistent and need confirmation.29 A recent study of Iso et al.30 identi-
fied a population of CD271+ MSCs released to the PB in acute MI reaching a peak number 
after 3 days and returning to levels comparable to healthy subjects by 1 week.  
 
Other acute cardiovascular events associated with mobilization of SPCs  
 
Stroke  
Cerebral ischemia leads to the mobilization of several populations of CD34+ cells, including 
HSCs and CXCR4+ lin⎯CD45⎯ VSELs expressing pluripotent markers (Oct-4, Nanog) and 
neural-specific markers (GFAP, nestin, bIII-tubulin, Olig1, Olig2, Sox2 and Musashi). The 
number of cells was positively correlated with stroke extensiveness. Increased numbers of 
HSCs and VSELs were observed 24 h after stroke and lasted for at least 7 days.31 On the 
other hand, the number of EPCs measured as CFU and their ability to form tubes in matrigel 
assay were reduced in acute stroke. The number of cells was measured, however, B1 week 
after the stroke, which might be too late to measure the ‘true’ reparative cells.32  
 
 
Limb ischemia  
EPC mobilization can be triggered by a single episode of limb ischemia induced by transient 
tourniquet occlusion of blood flow to one lower extremity in healthy volunteers, suggesting 
that this phenomenon is a fast-acting universal response to large tissue ischemia.33  
 
Cardiac non-ischemic injury  
Several clinical scenarios associated with major ischemia can lead to rapid release of SPC 
from the BM. Besides acute MI, another form of myocardial injury is the radiofrequency 
catheter ablation of atrial fibrillation, which was shown to induce the mobilization of CD34+ 
and was correlated with the extent of myocardial necrosis; however, this finding was not con-
firmed in other similar studies.34,35 In general, consistent findings suggest that substantial 
ischemia evokes a transient release of SPC from the BM, including populations with capacity 
of endothelial differentiation and induction of angiogenesis. It seems that the ischemia is a 
prerequisite for significant mobilization of EPCs, because, as shown by Adams et al.,36 the 
EPC number increased only in patients with inducible myocardial ischemia, but not in healthy 
subjects or patients without inducible ischemia. Also, in the hearts explanted from patients 
with chronic ischemic cardiomyopathy, the expression of chemoattractants (stromal cell-
derived factor-1 (SDF-1), stem cell factor, hypoxia-inducible factor-1a, hepatocyte growth 
factor) was increased in comparison with non-ischemic cardiomyopathy (dilated cardio-
myopathy). The number of circulating cells in ischemic cardiomyopathy was lower than in 
dilated cardiomyopathy, perhaps as a result of more effective homing signals.37  
 
Mechanisms of mobilization in acute cardiovascular events  
 
In acute MI, the systemic levels of soluble inflammatory mediators are significantly increased. 
Among inflammatory markers there are numerous factors that act as chemoattractants to BM 
SPC. It seemed appealing to assume that ischemic tissue releases the chemoattractants, 
which create the gradient directing to the site of injury and that the cells follow the migratory 
pathway created by increased levels of chemokines, cytokines and growth factors.1,38 The 
true mechanism is, however, more complicated, because, first, the plasma levels of 
chemokines (SDF-1) are not correlated with the extent of SPC mobilization; second, the 
measurement of plasma levels does not necessarily reflect the local concentrations in the 
BM and ischemic tissue, which is more important for cell egress and homing. Third, until re-
cently factors more important for SPC mobilization than circulating chemokines were un-
known, such as bioactive phospholipids (sphingosine-1-phosphate, activation of complement 
cascade and kinin–kallikrein system, including presence of bradykinin B2 receptor on circu-
lating EPCs).16,39,40 In general, the studies in patients with acute MI showed either weak cor-
relation between the number of EPCs and plasma VEGF levels, and CXCR4+ cells and 
plasma SDF-1 levels, or found no significant correlation at all. Most likely the timing of the 
blood sampling is crucial, because the early kinetics of SPC mobilization does not entirely 
overlap with prolonged inflammatory reaction.3,8,22,23 Several chemoattractants are signifi-
cantly upregulated in the viable ischemic area of the myocardium surrounding the necrotic 
infarct zone.41 Moreover, the significant correlations do not necessarily prove the causal link 
between the SPC number and soluble cytokine levels, due to the complexity of inflammatory 
reaction in ACS. Circulating SPCs express several receptors for cytokines, growth factors 
and chemokines. Data from animal and human studies suggest that the local milieu created 
in the infarct border zone may attract the circulating cells via several signaling pathways, 
including membrane receptors CXCR4 and CXCR7, interacting with chemokine SDF-1. 
CXCR4+ cells enriched for cardiac and endothelial markers show robust chemotactic re-
sponse to an SDF-1 gradient and expression of SDF-1 in ischemic myocardium was shown 
both in murine models and in human tissues. This chemokine has a pivotal role in the reten-
tion and mobilization of CXCR4+ SPC from the BM, and their homing and engraftment in the 
myocardium is basically a reverse process to mobilization. Other signaling pathways that 
might promote trafficking and engraftment of SPC are leukemia inhibitory factor– leukemia 
inhibitory factor receptor, hepatocyte growth factor–c-met, VEGF–VEGFR and stem cell fac-
tor–CD117. All of them are upregulated in acute MI.38,42 Figure 1 shows the mechanisms 
involved in mobilization of BM cells in acute MI and vascular endothelial injury (rupture of 
unstable plaque and stent implantation), and homing of SPCs to the site of injury.  
 
Factors modulating mobilization of SPC  
 
The absolute number of SPCs in PB is very low even in the setting of acute cardiovascular 
events, and their ability to engraft in the ischemic area is definitely limited, as shown in stud-
ies with intracoronary infusion of radiolabelled cells. Therefore, to properly interpret the dif-
ferences in the numbers of circulating SPCs, it is important to account for other factors that 
can modulate this process, including age, medications, profile of CV factors and major vas-
cular surgical procedures. In general, the number and function of circulating cells, particularly 
EPCs, is reduced in older subjects with coexisting cardiovascular risk factors, especially dia-
betes. Diabetes is associated with BM dysfunction, most probably associated with generation 
of reactive oxygen species, which translates into structural disorganization of vascular niche 
and dysfunction of BM MNCs.43 The number of circulating EPCs declines proportionally to 
the increasing number of cardiovascular risk factors (Tables 1 and 2). Ageing is associated 
with impaired function and viability of EPCs leading to decrease of endothelial reparatory 
potential.44 On the other hand, use of statins may reverse the process by increasing the mo-
bilization, and improving the viability, migratory and neovascularization capacity. In patients 
with stable CAD age is inversely correlated with the number and functional capacity of circu-
lating EPCs; however, the mobilization of these cells in acute MI is not significantly related to 
age.45 Conversely, we found that mobilization of primitive VSELs in acute MI is reduced in 
older patients.27 In addition, several other, non-cardiovascular clinical situations may alter the 
number and properties of circulating BM-derived SPCs, which supports the theory that this 
mechanism is universally involved in tissue repair (Table 3).  
 
Mobilization of SPCs and clinical outcomes in acute coronary syndromes  
In theory, the effectiveness of the mobilization reflects the intrinsic potential for tissue repair 
and could be a valuable prognostic marker. Observational studies suggest that mobilization 
of CD34+ cells is correlated with parameters of left ventricular function and remodeling 1 year 
after acute MI.23 In our study numbers of CD34+/CXCR4+ and CD34+/CD117+ in the early 
phase of acute MI showed positive correlation with left ventricular ejection fraction and nega-
tive correlation with NT-proBNP and cardiac necrosis markers. We showed that in patients 
with severely impaired left ventricular ejection fraction the mobilization of CD34+ cells and 
VSELs was significantly less effective than in patients with better contractility.46 The role of 
circulating CXCR4+ cells as a predictors of long-term improvement of left ventricular ejection 
fraction needs confirmation in larger groups of patients; however, the available data suggest 
that impaired mobilization of SPC might identify patients with more severe cardiac necrosis 
and dysfunction.27 It is unclear whether the inverse association between mobilization of BM 
cells and extent of myocardial infarct size is a result of more rapid engraftment of cells or 
signifies the impaired potential of myocardial healing. Data on the prognostic value of other 
populations of SPC in acute MI are conflicting.3,8,10 Moreover, not only the number of EPCs, 
but also their capability to differentiate into adult endothelial cells may affect functional im-
provement and infarct size reduction evidenced by nuclear scan, left ventricular ejection frac-
tion salvage and favorable remodeling in patients with AMI.47 The mobilization of EPCs 24 h 
after acute MI showed significant positive correlation with extent of viable ischemic myocar-
dium, but not with infarct size and microvascular obstruction. This supports the hypothesis 
that myocardial ischemia, and not necrosis, is a pivotal determinant of EPCs release from the 
BM.48 Also, the number of EPCs isolated from the arterial blood drawn from the coronary 
artery distally to the occlusion in acute MI was positively correlated with successful revascu-
larization measured by myocardial blood flow.49 The generalized vascular injury in cardiovas-
cular disease leads to a detachment of mature EC from the basement membrane and in-
crease in the cellular turnover. One might hypothesize that release of BM-derived EPCs 
should be sufficient to replace the detached EC and restore the functionally competent endo-
thelial layer. Therefore, measurement of these two populations should be considered a po-
tential tool for risk stratification, because it reflects not only the endothelial injury but also 
individual physiological repair response.20 It seems logical to interpret differently the release 
of SPCs triggered by acute ischemic injury (for example, MI) and fluctuations in their num-
bers in stable conditions, and minor vascular trauma. Endovascular procedures, such as 
insertion of coronary catheter and percutaneous coronary intervention with implantation of 
stent, lead to local injury of endothelium, evidenced by release of both CEC as a direct result 
of injury and EPCs, which is most likely the reparatory response.50  
 
Circulating BM cells and risk stratification in stable coronary heart disease and heart failure  
Stable CAD represents a situation entirely different from acute MI in terms of BM cell mobili-
zation. The number of cells constantly released might be considered to be the individual 
competence for endothelial repair to counterbalance the apoptosis and detachment of EC 
from the luminal surface of the artery. A prospective study of 519 patients with stable CAD 
demonstrated increased risk of CV associated with low number of circulating EPCs.51 Not 
only the number but also impaired function of EPCs displays negative correlation with CV 
risk.52 Hill et al.18 showed inverse correlation between the circulating EPCs and Framingham 
risk score in subjects without CAD. Interestingly, the number of circulating EPC count was a 
good predictor of endothelium-dependent vasodilatation.18 Recently published data from 
analysis of more than 1100 patients showed that measurement of circulating CPCs may 
have additional prognostic value, especially in patients with high risk of cardiovascular 
events. Suppression of SPC mobilization in heart failure is particularly evident in more severe 
classes of cardiac dysfunction. Several studies showed that measurement of circulating 
EPCs might predict the outcome, including all-cause mortality, in this population of high-risk 
patients.53 Therefore, the enumeration of circulating EPCs may be used in risk stratification, 
because it seems to reflect the global burden of CV risk factors.54  
 
Dysfunction of BM-derived cells  
 
Even if the mobilization of progenitor cells is targeted at reparatory reaction, it is obviously 
not sufficient to rebuild the necrotic tissue. One of the reasons is a relatively low number of 
cells in comparison with the extent of necrotic cells within the heart. Also, the populations of 
mobilized cells might be dysfunctional. Schwartzenberg et al.55 showed that in patients with 
ACS the number of apoptotic CD34+ Anexin V+ cells was significantly increased than in 
healthy controls and correlated with severity of coronary disease. Notably, in addition to al-
terations in the number of circulating or mobilized stem/progenitor cells in cardiovascular 
disease, several recent studies have clearly suggested that there is a major alteration of the 
CV-repair function, that is, the capacity to promote repair of endothelial or cardiac injury, me-
diated by circulating or mobilized stem/progenitor cells in patients with cardiovascular risk 
factors or established CV disease. The vascular or cardiac repair capacity of circulating SPC 
cells has been studied in numerous in-vitro and in several in-vivo functional assays, that is, 
frequently involving transplantation of patient-derived stem/progenitor cells into immunodefi-
cient animal models with either vascular or peripheral and cardiac ischemic injury. The im-
pairment of the vascular, that is, endothelial, repair capacity of ‘early EPCs’ likely is an early 
event in the CV disease process, as suggested, for example, by a recent study in patients 
with prehypertension as their only CV risk factor, who already had a markedly impaired endo-
thelial repair capacity of circulating ‘early EPCs’ that was largely mediated by paracrine fac-
tors. In this study, signs of aging, such as telomere shortening and increased galactosidase 
activity, were observed in patient-derived early EPCs.56 In patients with type-2 diabetes, sev-
eral studies have shown an impaired functional activity of ‘early EPCs’, including a loss of the 
capacity to promote endothelial repair.57,58 Interestingly, the mechanisms underlying the im-
paired endothelial repair function likely included a reduced endothelial No synthase-derived 
nitric oxide (NO) production of patient-derived cells.58 The aspect of an impaired CV repair 
function of circulating SPCs is also particularly relevant for autologous cell transplantation in 
patients with ischemic heart disease, where eligible patients are elderly, and frequently have 
several CV risk factors. Autologous patient-derived BM or circulating cells have therefore 
been evaluated in preclinical studies and in-vitro and in-vivo functional assays. BM-derived 
mononuclear cells isolated from patients with ischemic cardiomyopathy had an impaired pro-
angiogenic capacity when transplanted into mice with hindlimb ischemia.59 Moreover, several 
factors, including age, anemia, renal failure, high levels of C-reactive protein or interleukin-6, 
have been observed to correlate with a poor angiogenic potency of BM-derived mononuclear 
cells isolated from patients when examined after transplantation into mice with hindlimb 
ischemia.60 In addition, the in-vitro migratory capacity of infused BMCs and CPCs at the time 
of intra-coronary injection was closely related to cell-dependent reduction in infarct size in 
patients after acute MI.61 In the same line, transplantation of BMCs with a high mitogenic 
capacity in vitro as determined by colonyforming units was associated with significantly re-
duced markers of heart failure, namely NT-proBNP and NT-proANP, and mortality within 3 
months after injection.62 In addition, a recent study suggested the effect of an association 
between CV risk factors, in particular with an effect of active smoking, on the therapeutic 
benefit of intracoronary BMC transplantation to cardiac function, that is, patients who are 
active smokers may benefit less from intracoronary BMC injection as compared with non-
smokers as observed in the BONAMI trial (clinicaltrials.gov: NCT00200707).63 These obser-
vations may help identify likely responders and exclude patients who are not likely to receive 
benefit from cardiac cell transplantation.  
 
Physical exercise  
 
Regular exercise is one of the most important issues in primary and secondary prevention of 
cardiovascular events. In patients with CAD, the increased oxygen demand and myocardial 
ischemia during a single episode of exercise coexist with release of VEGF and mobilization 
of EPCs. The number of EPCs increases as soon as 10 min after the exercise and reaches 
its maximum after 24–48 h in patients with peripheral vascular disease (PVD). Prolonged 4-
week exercise program seems not only to prolong the mobilization of EPCs but also to im-
prove their function. This suggests that even in patients with diffuse atherosclerosis and mul-
tiple risk factors some reparative potential dependent on circulating BM-derived EPCs is re-
tained and that it can be enhanced in a most physiological way.36,64 Additionally, both maxi-
mal and endurance exercise can influence the numbers of both HSC and EPCs in healthy 
subjects. In the marathon runners (endurance exercise) the number of EPCs increased while 
erythropoietic and granulocyte monocyte colonies decreased after the run. On the other hand 
the field test (maximal exercise) led to increase of CD34+ and EPCs, as well as both types of 
hematopoietic colonies.65 Regular physical exercise is recommended to patients after ACS to 
improve the outcome. The beneficial effects of such training might be related to the improved 
mobilization and functional capacity of CPCs, as shown in patients with acute MI who under-
went a 3-week period of regular exercise. After the training period the number and migratory 
capacity of CPCs (CD34+/CD45+ and CD133+/CD45+) significantly increased. 66 Physical ex-
ercise can reverse the dysfunction of circulating angiogenic cells in patients with chronic 
heart failure. After a single episode of treadmill exercise, the migration and SDF-1 levels 
were comparable to healthy subjects. It remains, however, to be proven that regular exercise 
will lead to a sustained functional improvement of circulating angiogenic cells.67  
 
Future challenges  
 
In our opinion, the lack of consensus on the identity and methodology of measurement of 
EPCs is the most important limitation of discussed studies. To validate the clinical use in risk 
stratification, standardized protocols need to be developed and ‘normal’ values established. 
Also, the protocols for stem cell measurements will need to be simplified to be introduced 
into clinical practice. The incremental prognostic value of EPCs beyond the traditional risk 
factors has to be proved. Also, to move the field forward, the contribution of circulating SPCs 
to endothelial and myocardial repair in humans needs to be proven. Better understanding of 
the stem cell mobilization and homing will pave the way to introduce new pharmacological 
agents, which would stimulate the release of most potent populations of cells to achieve bet-
ter results.  
 Summary  
 
Acute CV-ischemic episodes induce the rapid mobilization of BM-derived cells. Subpopula-
tions of circulating cells may participate in myocardial and endothelial repair; however, the 
efficiency of this process in unknown. The number and function of these cells is impaired in 
patients with diabetes and other CV risk factors, but can be improved by physical exercise 
and use of statins. The mobilization of SPC in acute coronary syndromes and stable CAD 
seems to predict the clinical outcomes in selected groups of patients. Interpretation of the 
findings has to incorporate other factors that modulate the process of mobilization, such as 
coexisting diseases, age and medications, as well as the details of the assay protocols.  
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Figures: 
 
 
Figure 1 Mechanisms involved in mobilization of BM cells in acute MI and vascular endothe-
lial injury (rupture of unstable plaque and stent implantation), and homing of SPCs to the site 
of injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table1 Drug treatment modulating the stem/progenitor cell mobilization 
 
 
 
Table 2 Cardiovascular risk factors and cardiovascular invasive procedures modulating the 
number and/or function of circulating stem and progenitor cells 
 
 
 
Table 3 Non–cardiovascular clinical conditions and surgical procedures associated with changes of 
the number of circulating stem/progenitor cells 
